Dr. Bourgoin is a regular researcher at the Research Center of Quebec – Laval University and Professor in the Department of Microbiology-Infectiology and Immunology of the Faculty of Medicine at Laval University. His work focuses on lipid mediators of inflammation in systemic autoimmune diseases and dysfunction of innate immunity cells.
Dr. Bourgoin has published more than 100 articles in scientific journals (Google Scholar h-index of 39). His work has been the subject of several editorial reviews of scientific journals in 2108 (Molecular Pharmacology) and in 2011 (Journal of Leukocyte Biology). Dr. Bourgoin contributes to the influence of the CHU Research Centre and Laval University by organizing international symposia on neutrophils in immunity (2012, 2014, 2016, 2018).
Understanding early atherosclerosis in rheumatic autoimmune diseases:
Accelerated atherosclerosis, associated with systemic autoimmune diseases, such as lupus erythematosus and rheumatoid arthritis, significantly increases the risk of cardiovascular events. The lipid mediators of inflammation play an amplifying role in the development of atherosclerosis, promoting the recruitment of immune system cells and the thickening of the vessel wall. Strategies to reduce cardiovascular risks associated with lupus erythematosus and rheumatoid arthritis remain to be clarified.
A new target to treat leukemia:
Myeloid leukemias are blood cancers whose origin is an anarchic production of white blood cells, from the bone marrow. These cells are usually immature, and unable to fight infections. Their presence also tends to disrupt the production of red blood cells, and cause a decline in the production of platelets. Genetic and epigenetic modifications alter the expression or function of proteins that act as positive or negative regulators of proliferation. These molecular switches abundant in leukemic myeloid cells act as positive regulators of proliferation, while inhibiting their differentiation into functional white blood cells.
2705, boulevard Laurier
Canada G1V 4G2
Functional Role of AGAP2/PIKE-A in Fcγ Receptor-Mediated PhagocytosisJournal Article
Cells, 12 (1), 2022.
Phospholipase A1 Member A Deficiency Alleviates Mannan-Induced Psoriatic Arthritis in Mice ModelJournal Article
Int J Mol Sci, 23 (15), 2022.
Red blood cell-derived phosphatidylserine positive extracellular vesicles are associated with past thrombotic events in patients with systemic erythematous lupusJournal Article
Lupus Sci Med, 9 (1), 2022.
Corrigendum to "Arf6 regulates energy metabolism in neutrophils" [Free Radic Biol Med. 172 (2021) 550-561]Journal Article
Free Radic Biol Med, 179 , 2022.
Phospholipase A1 Member A Activates Fibroblast-like Synoviocytes through the Autotaxin-Lysophosphatidic Acid Receptor AxisJournal Article
Int J Mol Sci, 22 (23), 2021.
Interplay between LPA2 and LPA3 in LPA-mediated phosphatidylserine cell surface exposure and extracellular vesicles release by erythrocytesJournal Article
Biochem Pharmacol, 192 , 2021.
Arf6 regulates energy metabolism in neutrophilsJournal Article
Free Radic Biol Med, 172 , 2021.
Platelet EVs contain an active proteasome involved in protein processing for antigen presentation via MHC-I moleculesJournal Article
Blood, 138 (25), 2021.
Phosphatidylserine-specific phospholipase A1: A friend or the devil in disguiseJournal Article
Prog Lipid Res, 83 , 2021.
Human Inflammatory Neutrophils Express Genes Encoding Peptidase Inhibitors: Production of Elafin Mediated by NF-κB and CCAAT/Enhancer-Binding Protein βJournal Article
J Immunol, 206 (8), 2021.
- Role of autotaxin bound to platelet-derived microparticles to development of vascular damage in arthritis., from 2015-07-01 to 2023-03-31
- Role of phosphatidylserine-specific phospholipase A1 (PLA1A) in the pathogenesis of rheumatic diseases, from 2023-01-01 to 2025-12-31
Recently finished projects
- Profil moléculaire sanguin de patientes souffrant de lupus, from 2019-04-01 to 2021-03-31